Loading...
Cassava Sciences, Inc.
SAVA•NASDAQ
HealthcareBiotechnology
$2.12
$0.07(3.41%)
Cassava Sciences, Inc. (SAVA) Stock Overview
Explore Cassava Sciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-1.51
↑ 74.96%
EPS Growth
$-1.51
↑ 77.16%
Operating Margin
0.00%
↑ 100.00%
ROE
-46.29%
↑ 74.96%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
2
Hold
1
Sell
0
Strong Sell
0
Price Targets
Low$0.00
Average$0.00
High$0.00
Company Profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
CEO
Mr. Richard Jon Barry
Employees
30
Headquarters
7801 North Capital of Texas Highway, Austin, TX
Founded
2000